Ann: Presenting at Bell potter healthcare conference, page-10

AI, you need to think about the competition there. Molecular diagnostic space is very competitive. There's already big players occupying the space. Just to name a few, Roche, Abbott and Qiagen are already in big public/private labs in Australia. STD Screening isn't exactly an area of unmet needs. GSS has cost effective, slightly faster diagnostic panel which can definitely break into the scene but it won't exactly dominate the space. They'll take a piece of a big pie
Look back in a couple of years time, it'll be either acquired at a premium or at least $1B company.